background: The progesterone-regulated glycoprotein glycodelin-A (GdA), secreted by the decidualized endometrium at high concentrations in primates, inhibits the maternal immune response against fetal antigens and thereby contributes to the tolerance of the semiallogenic fetus during a normal pregnancy. Our earlier studies demonstrated the ability of GdA to induce an intrinsic apoptotic cascade in CD4 + T-lymphocytes and suppress the cytolytic effector function of CD8 + T-lymphocytes. In this report, we investigated further into the mechanism of action of GdA controlling perforin and granzyme B expression in CD8 + T-lymphocytes and the mechanism of action of GdA leading to lymphocyte death.
Introduction
The ability of the maternal immune cells to tolerate the semi-allogenic fetus is conferred by mechanisms which either suppress fetal allogenicity or spatio-temporally inhibit maternal immune cells' growth and functions (Pearson, 2002; Veenstra van Nieuwenhoven et al., 2003; Niederkorn, 2006; Trowsdale and Betz, 2006; Terness et al., 2007) . Glycodelin-A (GdA) or placental protein 14, a glycoprotein found specifically in primates, is synthesized by the luminal and glandular epithelium of the decidua and its concentration in the uterine compartment reaches up to 2.5 mM between 14 and 16 weeks of pregnancy (Seppala et al., 2002) . It is one of the immunomodulatory factors that augment fetal tolerance (Bolton et al., 1987; Tulppala et al., 1995) . GdA, a 162 amino acid secreted protein, is spatio-temporally regulated by progesterone (Joshi, 1983; Taylor et al., 1998) and functions as a galactose-specific lectin (SundarRaj et al., 2009 ) to bring about its inhibitory effects on maternal immune cells which are activated by the trophoblastic antigens at the fetal -maternal interface during pregnancy (van Kampen et al., 2001) .
The placenta, which is comprised of both fetal and maternal tissues, is the site of rigorous immune cell activity. It contains a diverse population of maternal immune cells; uterine natural killer (NK) cells, dendritic cells, T-lymphocytes, monocytes and B cells (Starkey et al., 1988; Williams et al., 2009) . GdA exerts its inhibitory effect on both innate and adaptive immune responses (Seppala et al., 2002) . Subjects with subnormal levels of GdA face unexplained infertility (Mackenna et al., 1993) , habitual abortions (Tulppala et al., 1995) and recurrent miscarriages (Dalton et al., 1998) . GdA inhibits the proliferation of B cells, along with reduced immunoglobulin M (IgM) secretion and major histocompatibility complex class II surface expression upon activation (Yaniv et al., 2003; ). Experiments carried out on peripheral NK cells and decidual large granular lymphocytes confirm the ability of GdA to inhibit their cytolytic activity (Okamoto et al., 1991) and to enhance interleukin-6 (IL-6), IL-13 and granulocyte-macrophage colony-stimulating factor production from them, signifying its role in trophoblast invasion (Lee et al., 2010) . Survival and proliferation of monocytes are inhibited (Tee et al., 2008; ) and dendritic cells derived from monocytes acquire a tolerogenic phenotype on GdA treatment (Scholz et al., 2008) .
The most extensively studied effect of GdA is that on the T-lymphocytes. GdA inhibits the proliferation of mitogen stimulated T-cells (Bolton et al., 1987; Pockley and Bolton, 1989; Rachmilewitz et al., 1999; Mukhopadhyay et al., 2001) . Additionally, it induces apoptosis in activated T-lymphocytes (Mukhopadhyay et al., 2001 ) and the protein backbone is necessary and sufficient for this activity (Jayachandran et al., 2004) . Importantly, the N-linked glycosylation on GdA modulates accessibility of the active site on the protein (Mukhopadhyay et al., 2004; Jayachandran et al., 2006; Poornima and Karande, 2007) . GdA also shifts the Th1-Th2 cytokine balance towards Th2 cytokines (Mishan-Eisenberg et al., 2004) by selectively triggering apoptosis in Th1 cells (Lee et al., 2011) . Interestingly, like the Th2 cells, B cells 
as well as CD8
+ Tlymphocytes are resistant to GdA-induced apoptosis (Soni and Karande, 2010) , though the proliferation (SundarRaj et al., 2009) and cytolytic potential of CD8 + CTLs (cytotoxic T-lymphocytes) are compromised upon GdA treatment (Soni and Karande, 2010) . Further exploring the regulatory effect of GdA on the effector functions of CD8 + T-cells, which predominate the uterine T-lymphocyte population during pregnancy (Williams et al., 2009) , we reported that GdA exerts its inhibitory effect on the cytolytic activity of CTLs by down-modulating the synthesis and release of key cytolytic factors perforin and granzyme B from them (Soni and Karande, 2010) . In this study, we have probed further into the mechanistic details of the regulation of perforin and granzymes by GdA. In agreement with the report by Pockley and Bolton (1989) , we find that GdA induces suboptimal IL-2 signalling, by down-regulating the surface expression of an IL-2Ra subunit (CD25), which together with reduced eomesodermin (Eomes) expression result into abated perforin and granzyme B contributing to the debilitated cytolytic activity of CTLs. Interestingly, our data suggest that the aberrant IL-2 signalling in the presence of GdA translates into a dis-balance between the pro-and anti-apoptotic proteins within T-cells. Thus, data reported in this study indicate that growth factor depletion may be a potential mechanism not only for the inhibition of proliferation but also for apoptosis and loss of effector functions induced by GdA in T-lymphocytes at the feto-maternal interface.
Materials and Methods

Cells and cell lines
Peripheral blood mononuclear cells (PBMCs) were isolated using 'Ficoll' density gradient centrifugation (Histopaque, Sigma-Aldrich, MO, USA), from fresh whole blood of normal healthy donors (males and non-pregnant females of the age group 25 -30 years; Boyum, 1964) . PBMCs were cultured in Roswell Park Memorial Institute (RPMI)-1640 medium (Sigma-Aldrich) supplemented with 10% fetal bovine serum (FBS; Gibco, NY, USA), 100 U/ml penicillin, 100 mg/ml streptomycin and 2 mM L-glutamine, unless mentioned otherwise. Ovarian carcinoma cell line OVCAR-3 (obtained from Prof. J. Hilgers, Vrije University, Amsterdam) was cultured in Delbecco's modified Eagle's medium (Sigma-Aldrich) supplemented with 10% FBS, 2 mM L-glutamine and antibiotics.
Antibodies and reagents
Anti-CD4 and CD8 monoclonal antibodies (mAbs) were purified from culture supernatants of OKT4 and OKT8 hybridoma cells [National Facility for Animal Tissue and Cell Culture (NFATCC), Pune, India] cultured in Iscove's modified Dulbecco's medium (IMDM) with 10% FBS, using protein-A affinity chromatography. Purified Abs were labelled with FITC using the standard protocols (Bioconjugate Techniques by Greg T. Hermanson, second edition). Anti-Eomes Alexa Fluor R 647, anti-human CD25-PE, anti-human Bcl-2 and anti-human Bax antibodies were purchased from eBiosciences (USA). Anti-human beta-actin horse-radish peroxidase (HRP) conjugate, anti-human interferon (IFN)-g-PE conjugate, HISTOPA-QUE, PHA (phytohaemagglutinin) and RNA isolation reagent (TRI reagent) was purchased from Sigma-Aldrich. Rabbit anti-mouse HRP-conjugated antibody was procured from Dako (Denmark). RevertAid reverse transcriptase, Oligo-dT and dNTP mix was obtained from Thermo Fisher Scientific (Canada). For real-time PCR analysis, iQ SYBR Green sensimix was procured from Bio-Rad (CA, USA). CD4 + and CD8 + T-cells were isolated using magnetic-activated cell sorting (MACS-Meltenyi Biotec, Germany), by the MS-MACS columns using streptavidin-phycoerythrin microbeads.
Purification of GdA
GdA was purified from amniotic fluid by immunoaffinity chromatography, using a Gd-specific mAb, D9D4 using the standard lab protocol (Mukhopadhyay et al., 2001) . Briefly, GdA was eluted with 100 mM gly -HCl, pH 2.5, and neutralized with 1 M Tris-HCl, pH 8.0, thereafter dialysed against 50 mM phosphate-buffered saline (PBS). The purity of the protein was determined using sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) followed by silver staining and specificity ascertained by western blotting. The protein preparations were checked for LPS (lipopolysaccharide) contamination using E-Toxate, LPS detection kit (Sigma-Aldrich). Protein preparations free of LPS contamination were used in all the assays. Also, the activity of GdA was ascertained by cell proliferation and apoptosis assays (Soni and Karande, 2010) . One of the most abundant proteins of the amniotic fluid, namely human serum albumin (HSA), was purified from amniotic fluid (Mukhopadhyay et al., 2001) and has been used as the negative control throughout the study.
Alloactivation and T-cell stimulation
To activate PBMCs and to generate CTLs in vitro, a previously standardized method of alloactivation was followed (Soni and Karande, 2010) . Briefly, PBMCs (responders) were alloactivated, using gOVCAR-3 (OVCAR-3 cells irradiated with 30 Gy of gamma rays using the BI-2000 gamma irradiator), as stimulators. Stimulators were co-cultured with responders in a ratio of 1:10 in IMDM supplemented with 10% FBS, 10% normal human serum, 2 mM sodium pyruvate and 2 mM L-glutamine in 60 mm culture grade Petri plates, at a cell density of 6 × 10 6 /ml for 96 h at 378C in 5% CO 2 . About 5 U/ml of recombinant IL-2 (Sigma-Aldrich) was supplemented at 0 and 48 h of the co-culture. Depending on the requirement of the experiment, the alloactivation was either terminated after 18 h of co-culture or continued for 96 h or both and has been mentioned wherever necessary. Cells were treated with GdA for 24 h post-alloactivation. Alternatively, purified PBMCs (2.5 × 10 6 cells/ml) were activated with 5 mg/ml of PHA for 18 h (or as mentioned) in RPMI supplemented with 10% FBS. PHA-stimulated cells were simultaneously treated with GdA unless mentioned otherwise.
Cell surface/intracellular staining and flow cytometry
For cell surface staining, activated cells (1 × 10 6 ) were stained with anti-CD4-FITC/CD8-FITC and/CD25-PE direct conjugates (as indicated) or anti-CD28 for 1 h on ice. Direct conjugates were washed twice with fluorescence-activated cell sorting (FACS) wash buffer [0.2% bovine serum albumin (BSA) (w/v) and 0.1% (w/v) sodium azide in 50 mM PBS], fixed with 2% paraformaldehyde and stored at 48C until acquisition on FACSCalibur/Canto II flow cytometer (Becton Dickenson, NJ, USA). Acquired data were analysed using WinMDI 2.9 software/Cell Quest Pro and plotted using Graph Pad Prism Ver 5.0. Anti-CD28 surfacelabelled cells were washed with FACS wash buffer and then probed with Rabbit-anti-mouse FITC conjugate (Dako), washed to remove unbound secondary antibody and then fixed with 2% paraformaldehyde. Data were acquired and analysed as aforementioned. In all cases, at least 10 000 events were acquired per sample for analysis.
Intracellular staining: for staining secreted proteins like IFN-g, PBMCs were cultured with 2 mM monensin (Sigma-Aldrich) for the last 12 h during the 18-h alloactivation and also during 24 h of GdA treatment. Thereafter, the same protocol was followed for secreted or intracellular proteins. Cells (up to 1 × 10 6 ) were surface stained with desired antibodies against various surface markers, fixed with 2% paraformaldehyde (pHCHO), for 15 min at RT, washed to remove pHCHO followed by permeabilization with 1 ml of 90% methanol in 50 mM PBS (pH 7.2) for 30 min on ice. Cells were then centrifuged at 1957 g for 15 min to remove methanol and washed twice with FACS wash buffer, resuspended in 100 ml of FACS wash buffer and incubated with either anti-IFN-g-PE or anti-Eomes-Alexa Fluor for 1 h on ice. Washed to remove the excess antibody and stored at 48C until acquisition by FACS Canto II (Becton Dickenson). Data were analysed using BD FACSDiva 6.0/Cell Quest Pro software. At least 20 000 events were acquired per sample.
RNA preparation and real-time quantitative RT-PCR
Total RNA was isolated using TRI reagent (Sigma-Aldrich) from unactivated PBMCs, alloactivated PBMCs (18 or 96 h) treated with control protein (HSA) and alloactivated GdA-treated (24 h) PBMCs. 2.5 mg of total RNA was reverse transcribed in a vol of 20 ml using random hexamers (olig-dT) and RevertAid M-MuLV reverse transcriptase as per the manufacturer's instructions. Real-time quantitative PCR was performed using the DNA-binding dye, the SYBR Green method (Morrison et al., 1998) . Reaction was carried out in triplicates in 20 ml on a BioRad iCycler iQ 5 . The primers used for real-time PCR are listed in Table I . The amplification conditions for housekeeping and test genes were: initial denaturation at 958C for 3 min followed by 40 cycles of denaturation at 948C for 10 s, primer annealing at 638C for 30 s and extension at 728C for 45 s. The final extension was carried out at 728C for 5 min. The fluorescence emitted at each cycle was collected for the entire period of 45 s during the extension step of each cycle. The homogeneity/specificity of the PCR amplicons was verified by running 2% agarose gels and also by melt curve analysis. Mean Ct values generated in each experiment using the iCycler software (Bio-Rad) were used to calculate the relative fold change in gene expression upon activation and GdA treatment. Briefly, data for the test genes were normalized with reference gene (h18S rRNA) and calculated manually as the fold change in test gene expression above control (unactivated PBMCs) by the 2 2△△Ct method. Final fold change in gene expression was plotted using Graph Pad Prism 5.0 software. Statistical analysis was performed using the paired Student's t-test.
Cell lysate preparation and immunoblotting
Resting or PHA-activated PBMCs, treated with control protein or GdA, were washed with 50 mM PBS and pelleted at 2000 rpm/5 min. Cell pellets were blotted to remove any remaining PBS. Pellets were tapped and cells lysed for 30 min on ice in RIPA buffer (100 ml for 1 × 10 7 PBMCs) consisting of 50 mM Tris -HCl (pH 7.4), 1% Nonidet-P-40, 0.25% sodium deoxycholate, 150 mM NaCl, 1 mM EDTA, 1 mM phenylmethylsulphonyl fluoride, 1 mg/ml each of aprotinin, leupeptin and pepstatin (added freshly), 1 mM Na 3 VO 4 and 1 mM NaF. Samples were then vigorously vortexed and centrifuged at 14 000 rpm for 10 min at 48C. Pellet was discarded and protein estimated using Bradford's method of protein estimation. Equal protein from each sample was boiled in SDS sample buffer and subjected to SDS -PAGE along with a molecular weight marker. After equilibration in transfer buffer (25 mM Tris-base, 192 mM glycine and 20% methanol) gels were transferred onto nitrocellulose membrane (Millipore, MA, USA) by semi-dry western blotting (Bio-Rad). Non-specific binding was blocked with 5% non-fat dry milk powder in Tris-buffered saline Tween-20 (TBS-T; 20 mM Tris -HCl, pH 7.4, 137 mM NaCl and 0.1% Tween-20) for 2 -3 h at 48C with constant rocking. The blots were thereafter incubated overnight with constant rocking at 48C, with primary antibodies diluted in TBS-T with 5% BSA. Thereafter, blots were thoroughly washed with TBS-T and then incubated with anti-mouse IgG secondary antibodies conjugated with HRP for 1 h at 48C. After further washing in TBS-T, the immunoblots were developed with an enhanced chemiluminiscence detection system (Millipore) as per instructions. Data acquired using Fujifilm Las 3000 Imager and densitometric analysis was done using Fujifilm Multigauge software.
Statistical analysis
All the data were evaluated using the paired Student's t-test. P-value of ,0.05 was considered as statistically significant. 
Activated PBMCs upon GdA treatment express lower level of Eomes
In our previous study, we reported that GdA suppresses the cytolytic activity of CTLs generated in vitro by impeding the transcription of cytolytic genes viz. perforin and granzyme B (Soni and Karande, 2010) . We went further to find out how GdA controls the expression of perforin and granzyme B. T-box transcription factors T-Bet and Eomes induced upon the CD8 + cell activation act as key regulatory proteins in the development of competent effector and memory CD8 + T-cells (Szabo et al., 2000 (Szabo et al., , 2002 Pearce et al., 2003; Araki et al., 2008) . To test the possibility, if GdA was able to downmodulate the cytolytic effector genes by affecting the induction of Eomes and T-bet, we ascertained the transcriptional status of T-Bet and Eomes by real-time RT -PCR analysis. PBMCs alloactivated with gOVCAR-3 for 18 or 96 h were treated with 1 mM GdA for 24 h (which is the time required for GdA to have its inhibitory effect on CTLs). Two time points were chosen so as to pick the message at the time of its optimal synthesis. RNA was isolated and real-time RT -PCR was performed. Figure 1a and b depicts the expression of T-Bet and Eomes mRNA, respectively, in alloactivated PBMCs, expressed as fold change relative to the unactivated PBMCs. As is evident from the graph, there was no significant change in T-bet mRNA expression upon GdA treatment, but transcription of Eomes was significantly impeded by GdA (P ¼ 0.03). The result prompted us to look at the intracellular protein profile of Eomes. Unstimulated PBMCs, alloactivated PBMCs (24 h) followed by control/1 mM GdA treatment for 24 h, were stained for Eomes. Figure 1c shows representative histograms with the expression level of Eomes in resting and alloactivated PBMCs. Figure 1d depicts the % Eomes positive cells from five independent experiments. As is evident from the plots, GdA treatment reduced the intracellular protein level of Eomes. Interestingly, we did not observe any change in the intracellular IFN-g protein expression in activated CD8 + T-cells upon GdA treatment (Supplementary data, Fig. SI) .
GdA dampens CD25 expression in T-lymphocytes
We observed in stimulated CD8
+ T-cells that upon GdA treatment, they were cytolytically disabled and expressed relatively low levels of perforin and granzyme B (Soni and Karande, 2010) . Furthermore, our observation that upon GdA treatment, Eomes expression in activated T-cells was reduced ( Fig. 1) indicated that GdA induced a lowperforin, low-granzyme, low-Eomes profile, which was indicative of weak IL-2 signalling (Belz and Masson, 2010) . Most importantly, very early in glycodelin research, it was reported that GdA suppresses IL-2 synthesis in mitogen-stimulated T-cells and that exogenous supplementation of IL-2 can rescue T-cells from the GdA-induced inhibition of proliferation (Pockley and Bolton, 1989) which was further confirmed by a recent study (Lee et al., 2009) . Building up on the available information, we looked at the mRNA level (at an early and late time point of activation) and surface expression of CD25 in stimulated PBMCs. As expected, we observed a significant decrease in CD25 mRNA expression in PBMCs alloactivated for 18 and 96 h (Fig. 2a) , plate bound anti-CD3-activated and PHA-activated PBMCs (data not shown) upon treatment for 24 h with 1 mM GdA. Figure 2b shows the kinetics of CD25 surface expression upon PHA stimulation. Its expression started at around 6 h post-stimulation, peaked at around 18 h (at 24 -30 h in alloactivated PBMCs). Clearly a CD25
hi/bright and a CD25 lo/dim population could be seen, as indicated in the figure. The expression was fairly sustained until 48 h of stimulation.
To ascertain the effect of GdA on CD25 surface expression, PBMCs were stimulated with PHA for 24 h and simultaneously treated with GdA and surface stained for CD4/CD8 and CD4/ CD25. As can be seen in the representative dot plot in Fig. 2c 
GdA does not affect the expression of CD28 or CTLA4
CD28 and CTLA4 (CTL-associated protein 4) are immunoglobulin superfamily proteins expressed on the T-cell surface and are ligands for the B7 molecules (B7-1 and B7-2), which are constitutively expressed on antigen presenting cells and act antagonistically. CD28 (present on resting and activated cells) delivers a positive co-stimulatory signal, while signalling through CTLA4 (present only on activated T-cells) is inhibitory. We reasoned that GdA might exert its inhibitory effect on T-cells by affecting CD28 or CTLA4 levels; hence, we looked at the mRNA and protein profile of CD28 and the mRNA expression of CTLA4 in 18 or 96 h alloactivated PBMCs treated with GdA for 24 h. We did not observe any significant variation in the CD28 mRNA/protein upon GdA treatment (Supplementary data, Fig. S2a and b ) Similarly, CTLA4 mRNA expression was also found to be unaffected by GdA (Supplementary data, Fig. S3 ).
GdA signals to down-regulate Bcl-2 and up-regulate Bax in activated PBMCs
Three distinct IL-2R signalling pathways are reported to exist, mediated by c-myc, lck and Bcl-2 (Miyazaki et al., 1995) . Resting T-cells gain metabolic activity following the recognition of cognate Ag by the T cell receptor (TCR); yet, they do not progress to S-phase and instead undergo apoptosis, unless additionally stimulated by IL-2 or other mitogenic cytokines (Akbar et al., 1996; Van Parijs et al., 1997) . Bcl-2 and Bcl-x have been proposed to augment cell viability because constitutive expression of these genes in cytokinedependent cell lines significantly delays the onset of the apoptotic program induced by growth factor deprivation (Deng and Podack, 1993) . In the light of the above literature, we probed into the mRNA and protein expression status of important anti-apoptotic protein Bcl-2 in activated PBMCs upon GdA treatment. Supplementary data, Fig. S4 shows the fold induction of Bcl-2 mRNA in control-treated and GdAtreated alloactivated (18/96 h) PBMCs. There was a modest downregulation of Bcl-2 mRNA upon GdA treatment; however it did not reach statistical significance (n ¼ 6). Interestingly though, the assessment of total Bcl-2 protein levels from the cell lysates prepared after PHA activation and simultaneous GdA treatment of PBMCs for 24 h showed a moderate but a significant decrease (n ¼ 6). Essentially, the modest increase seen in Bcl-2 expression upon activation was abrogated in the presence of GdA and the Bcl-2 levels were similar to the resting PBMCs ( Fig. 3a and b) .
Bcl-2 and Bax proteins are known to heterodimerize that prevents Bax oligomerization and subsequent permeabilization of the outer mitochondrial membrane by Bax (Oltvai et al., 1993; Hengartner, 2000) . Hence, we went ahead to check for the expression profile of the pro-apoptotic protein Bax in alloactivated PBMCs upon GdA treatment. For RNA analysis, PBMCs were allostimulated for 18 h, treated with GdA for 24 h. For protein assessment, PBMCs were PHA activated along with GdA for 24 h and processed for total protein extraction. RNA analysis by real-time RT-PCR revealed an almost 5-fold up-regulation in Bax mRNA in the presence of GdA (n ¼ 5; Fig. 4a ). In concurrence, there was a significant increase in the total Bax protein upon GdA treatment of PHA-stimulated PBMCs (n ¼ 4; Fig. 4b and c) .
Discussion
Many studies have put forward mechanisms to explain the inhibitory effect of GdA on T-lymphocytes. Rachmilewitz et al. show that the inhibitory function of GdA is dependent on its localization to the phosphatase CD45 at the site of TCR triggering, where it negatively regulates T-cell activation by reducing the half-life of TCR-triggered phosphotyrosines (Rachmilewitz et al., 2001 . Delineating the mechanism of induction of apoptosis in T-lymphocytes, SundarRaj et al. (2008) provide compelling evidences of a TCR-independent pathway, wherein GdA induces a stress signal which culminates into mitochondrial membrane potential loss and permeabilization, causing T-lymphocytes to apoptose via the intrinsic mitochondrial pathway. Corroborating these data, overexpression of Bcl-2 and prevention of mitochondrial membrane permeabilization are sufficient to rescue T-cells from death by GdA (SundarRaj et al., 2008) . Pockley and Bolton (1989) and Lee et al. (2009) attribute the immunosuppressive effect of GdA to its ability to cause inhibition of IL-2 synthesis in T-lymphocytes. We have reported earlier that GdA induces functional ineptness in differentiated CD8 + T-cells by blunting the synthesis and release of cytolytic molecules (Soni and Karande, 2010) . We began this study with the simple objective to further unravel the mechanism regulating the expression of perforin and granzyme B in alloactivated CD8
+ T-cells upon GdA treatment. From the available literature, we knew that T-Bet, Blimp-1, Eomes and Bcl-6 are the known transcription factors regulating CD8 + T-cell effector functions.
Among them, under antigen-specific stimulation conditions, T-Bet is required for the differentiation of naïve CD8 + T-cells to effector
CTLs and also for the IFN-g synthesis by these cells (Sullivan et al., 2003) . Also, Eomes complements T-bet functions and plays a major role in memory CD8 + T-cell development (Intlekofer et al., 2005 ).
So we looked at the effect of GdA on the induction of the two transcription factors, T-Bet and Eomes upon activation. We found that with GdA treatment, T-bet was unaffected but Eomes was significantly down-regulated both at the RNA and at the protein level (Fig. 1) . It is well established that the quality and magnitude of the CD8 + T-cell responses is governed by the strength of the stimulatory signal, cytokine milieu and availability of 'CD4 help'. These factors help shape the transcriptional program in the responding CD8 + T-cells which in turn affect their phenotypic and functional attributes. We reasoned that GdA could potentially hamper Eomes expression by affecting the stimulatory signals to the cells during activation (attributable to its property of being a lectin; SundarRaj et al., 2009) or by altering the cytokine milieu through its inhibitory effect on CD4 + T-cells, whose survival and functions are known to be affected by GdA. First, we looked at the effect of GdA on CD28 and CTLA4 which are required for accelerating or braking T-cell proliferation upon activation, necessary for T-cell homeostasis. GdA did not affect the expression of CD28 on T-cells; CTLA4 was also not up-regulated upon GdA treatment, suggesting that GdA (most likely) did not perturb the pro-or anti-stimulatory signals generated upon T-cell activation.
Our knowledge about the involvement of IL-2 in the development of CD8
+ T-cell effector and memory functions (Pipkin et al., 2010) and that GdA suppresses IL-2 production by stimulated T-cells (Pockley and Bolton, 1989) prompted us to check for CD25 expression as the read out for IL-2 signalling in both CD4 + and CD8 + T-cell subsets upon GdA treatment. It is well known that responsiveness to IL-2 is controlled by the IL-2R complex, which is composed of the high-affinity IL-2R a chain (CD25), the IL-2R b chain (CD122) and the common g chain (CD132), and that signalling through IL-2Ra is essential for protective immunity (Williams et al., 2006) . We observed that CD25 mRNA and protein expression were significantly reduced upon GdA treatment in both the T-cell subsets, suggesting weak IL-2 signalling in the presence of GdA (Fig. 2) . Our finding was strengthened by the observations made by other researchers, i.e. high IL-2 signals induce transcription factors like STAT5 and Eomes which directly bind to perforin and granzyme gene locus and the amount of IL-2 signalling regulates the recruitment of polymerase II to the perforin (high IL-2) or the IL-7R (low IL-2) loci and that lack IL-2Ra expression on CD8 + T-cells causes aberrant killing of virally infected cells (Pipkin et al., 2010) . Additionally, a modest difference exists in effector molecules expression between CD25 hi and CD25 lo T-cells (Kalia et al., 2010) , with CD25 lo CD8 + T-cells expressing fewer cytolytic molecules. Thus, these findings indicate that the interaction of GdA with activated CD4
+ and CD8 + T-cells suppresses IL-2/IL-2R signalling induced upon T-cell activation, which seems to be the causative agent for the loss of proliferation of T-cells upon GdA treatment. Additionally, aberrant IL-2R-mediated signalling also contributes to reduced expression of cytolytic genes (perforin and granzyme B) in CD8 + T-cells, which are directly controlled by IL-2 as well (Janas et al., 2005) . Consolidating data from our previous work (Soni and Karande, 2010) and this study, we can say with much confidence that in CD8 + T-cells, GdA induces suboptimal IL-2 signalling that leads to the inhibition of proliferation and suppression of perforin and granzyme synthesis directly and also indirectly by suboptimal induction of Eomes. T-bet levels were unaffected by GdA which explains the moderate effects of GdA seen on CD8 + T-cells and the requirement of a very high concentration of GdA to affect CTL activity (Soni and Karande, 2010) . It also explains why there was no significant effect of GdA treatment on IFN-g production in CD8 + T-cells. We can envisage that a reduction in Eomes expression by GdA might also contribute to lowered number of CD8 + T-memory cells, further contributing to fetal tolerance. Studies on total T-lymphocytes clearly demonstrate that in addition to promoting proliferation, IL-2Ra expression also prevents apoptosis of T-cells, by up-regulating Bcl-2 expression (Gomez et al., 1998) . We observed a reduction in CD25
hi/bright surface expression on T-cells upon GdA treatment (Fig. 2d) . Previous work from our laboratory attributed the apoptogenic activity of GdA on primary T-cells and T-cell lines via the intrinsic mitochondrial pathway (Mukhopadhyay et al., 2001; SundarRaj et al., 2008) , which could be competed out by the overexpression of Bcl-2 (SundarRaj et al., 2008) . We questioned whether suppression of CD25 expression by GdA was causing a stoichiometric imbalance between the pro-and anti-survival proteins within T-cells. Indeed, we found that GdA treatment did not allow an increase in the Bcl-2 protein level within cells which is otherwise observed in activated T-cells (Fig. 3 ), although at the mRNA level, the decrease was not found to be statistically significant. Interestingly though, pro-apoptotic protein Bax was up-regulated at both the mRNA and the protein level (Fig. 4) . At least four proteins Bcl-2, 14-3-3, humanin and Ku-70 have been shown to inhibit apoptosis by binding to Bax and sequestering it from the mitochondria (Amsel et al., 2008) . With the data available on the activity of GdA and from the present study, we can surmise that the perturbation in the ratio of Bcl-2 and Bax leads to the availability of free Bax to oligomerize and initiate mitochondrial membrane permeabilization leading to apoptosis. This phenomenon seems to operate in CD4 + T-cells, where the suboptimal IL-2R expression may lead to a reduced IL-2 level which is insufficient to support the optimal up-regulation of Bcl-2 upon T-cell stimulation, necessary for survival. Unable to cope with the mitochondrial stress, CD4 + T-cells undergo apoptosis. Intriguingly, although the CD8 + T-lymphocytes have reduced CD25 expression upon GdA treatment, they are resistant to GdA-induced apoptosis (Soni and Karande, 2010) . Similarly, the Th2 cells are also resistant to GdA-induced apoptosis (Lee et al., 2011) , suggesting that the process of apoptosis induction may not be as simplistic and there may be many more players involved that may vary in different T-cell subsets. The different mechanisms put forth by various researchers to explain GdA activity on different cell types can be explained by the fact that GdA functions as a galactose-specific lectin (SundarRaj et al., 2009) , and it can potentially bind to varied glycosylated proteins on the T-cell surface Yaniv et al., 2003; SundarRaj et al., 2009) . Among the many potential candidates as the receptor for GdA on T-cells, CD45 and CD7 are the most extensively discussed. We observed that GdA-induced apoptosis in T-cell lines in a CD7-dependent manner (SundarRaj et al., 2009) . GdA treatment itself did not affect the expression of CD7 on both the T-cell subsets (data not shown). CD7 is known to augment T-cell proliferation/function by up-regulating CD25 expression and IL-2 production (Wallace et al., 2000; Stillwell and Bierer, 2001) . Very interestingly, CD7-deficient mice show decreased CTL effector functions (Lee et al., 1998) . Until now, a definitive ligand for CD7 is not known and only lectins have been proposed to be potential CD7 ligands (Leta et al., 1996) . Considering the fact that glycodelin is also a lectin, it will be interesting to probe whether glycodelin might exert its inhibitory effect on T-cells by interacting with CD7 and inhibiting its normal co-stimulatory function.
Altogether, from the present study and available literature, it can be proposed that the binding of GdA to CD4
+ and CD8 + T-cells blocks the co-stimulatory signals required for optimal CD25 expression and hence IL-2 production. Resultant suboptimal IL-2 signalling has varied effects; (i) cell cycle arrest as seen in both the major T-cell subsets; (ii) reduced induction of Eomes that causes retarded synthesis of cytolytic genes, causing suppression of CTL activity in CD8 + T-cells;
(iii) insufficient induction of anti-apoptotic genes upon T-cell activation, which increases the ratio of pro-to anti-apoptotic proteins, affecting mitochondrial integrity, finally leading to cell death in some CD4 + T-cell subsets. The mechanism of GdA activity suggested here seems to be operational in vivo and the expression of CD25 has also been found to be selectively reduced on decidual CD4
+ and CD8 + T-lymphocytes in normal pregnancies (Chao et al., 2002) . Nevertheless, it is important that similar studies be carried out using decidual T-lymphocytes to further confirm the effects of GdA seen on peripheral T-cells, as the localized abundance of progesterone in the uterus during pregnancy may alter the activity of GdA on decidual T-cells. It will also be pertinent to mention here that peripheral T-cells from men and women (at different times in their menstrual cycle), used as the model system for this study, are exposed to varying concentrations of serum progesterone and oestrogen, which may have a bearing on the effect of glycodelin on the T-cells and can be an interesting factor to study in depth.
In conclusion, the results put forth in this study demonstrate a previously unappreciated/underplayed effect of GdA on IL-2/IL-2R signalling. IL-2 growth factor deprivation can explain effects of GdA on T-cells, including the inhibition of proliferation, apoptosis and loss of effector functions which contribute to the establishment, progression and maintenance of primate pregnancy but the variations observed in the responsiveness of different cell types to GdA indicate that the understanding of the mechanistic details of GdA activity on hematopoietic cells is still far from complete.
